|
Pennsylvania
Bextra®
lawyer.
Speak to your doctor right away
about alternatives to this drug.
Withdrawal
On
April 7, 2005 the FDA announced that it has asked Pfizer, Inc.
to withdraw Bextra from the
market "because the overall risk versus benefit profile for
the drug is unfavorable."
Only
a few months ago Bextra® was required to add warnings
to it's box strengthening previous warnings about the risk of life-threatening
skin reactions and a new bolded warning contraindicating
(not using) it for patients undergoing coronary artery bypass
surgery.
|
Attorney
Information
|
FDA
Information |
| For
a free case evaluation from a Pennsylvania attorney, click here:
lawforum |
To read the
FDA's announcement withdrawing
Bextra |
| Munley,
Munley & Cartwright, P.C. is a Pennsylvania law office which
has breaking news and information about this lawsuit |
To
report any unexpected adverse or serious events associated
with the use of Bextra® contact the FDA MedWatch program
on the internet or at 1-800-FDA-1088 |
Side
Effects for Bextra or Valdecoxib include the following:
-
Potential
for increased risk of cardiovascular events
-
Gastrointestinal
bleeding
-
Serious
skin reactions, some resulting in death.
What
is Bextra?
Bextra®
is a non-steroidal anti-inflammatory drug
(NSAIDs), known as a COX-2 selective agent. It is
prescribed for inflammation and pain from arthritis or menstrual
cramping. Other drugs in this class include Celebrex® and
Vioxx®. Bextra® and Celebrex® are both marketed by
Pharmacia Corporation and Pfizer and Vioxx® is manufactured by
Merck. Doctors switched patients from Vioxx® to Bextra®
when Merck voluntarily removed it from the market due studies
showing an increased risk for heart attack and stroke.
bextra
site map
Autism
Education Materials!
|
